UNSPSC 51401510: Medazepam

This classification denotes a benzodiazepine with the molecular formula C16H15ClN2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier P0J3387W3S, chemically known as 2,3-dihydro-7-chloro-1-methyl-5-phenyl-1h-1,4-benzodiazepine but generally known as medazepam, which bears US NIH Compound Identifier 4041. European Medicines Agency schedules Medazepam in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08689MIG.

UNSPSC 51401510 Medazepam is a Commodity code that captures state and local procurement of pharmaceuticals and related health products, though recent solicitations tagged under this code reveal a broader pattern of acquisitions spanning naloxone, safe drug deactivation systems, generic multi-source pharmaceuticals, and over-the-counter products. State and local governments—counties, state health agencies, and cooperative purchasing alliances—use this code when sourcing pharmaceuticals and health-related products to support community health initiatives, pharmacy benefit programs, and emergency response capabilities. Issuing bodies include county health departments, state health and human services commissions, and multistate cooperative purchasing consortiums; Seminole County, Florida and the Texas Health and Human Services Commission appear in recent activity, alongside the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), which administers contracts across multiple participating states including Oregon. Vendors must typically meet federal compliance requirements including Drug Supply Chain Security Act (DSCSA) certification, current Good Manufacturing Practices (cGMP), FDA approvals, and E-Verify workplace authorization; insurance coverages are substantial (commercial general liability often $5 million per occurrence and professional liability $2 million) and contracts commonly include performance penalties for non-compliance and supply-chain audits.

Recent activity spans Florida, Texas, and the MMCAP consortium covering Minnesota and Oregon. Seminole County issued IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries, response due July 26, 2023 (note: date appears erroneous in source). The Texas Health and Human Services Commission posted RFI HHS0017013 in April 2026 to gather vendor capabilities for a Therapeutic Pharmacy Initiative direct-to-manufacturer prescriptions program, response deadline April 3, 2026. MMCAP issued RFP S1070000015802 in January 2026 for generic multi-source pharmaceuticals and OTC products distributed through three authorized wholesalers (AmerisourceBergen, Cardinal Health, Morris & Dickson), with proposals due March 26, 2026 and contract effective July 1, 2026; evaluation weights pricing competitiveness at 75 percent and require vendors to maintain relationships with at least two of the three authorized wholesalers.